WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
Strategic focus on COCO-model with a nationwide reach of 501 stores
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
The acquisition will strengthen the overall company’s position as leading global CRO services partner
he company will focus on production of any pharmaceutical and biotechnological products
Poor oral health (periodontal disease) impacts nearly 51% of Indians
USFDA completes PAI of Lupin’s biotech facility in Pune
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Subscribe To Our Newsletter & Stay Updated
